US expands MYOVIEW use:
This article was originally published in Clinica
The US FDA has given Amersham Health the green light to expand the use of its radiopharmaceutical imaging agent, MYOVIEW, in the diagnosis of heart disease. The product, which is already used to diagnose heart disease by visualising blood flow to the heart muscle, can now be used to assess left ventricular function (left ventricular ejection fraction and wall motion). The new indication provides "critical functional information to the well accepted perfusion assessment to better diagnose a patient's cardiac health", the UK firm says.
You may also be interested in...
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.